Delivery Order SPE2DB22D2206-SPE2DB25FJL30
Award Date 8/15/25
Potential Completion Date 8/18/25
Potential Value $28K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ontruzant 150 mg vials, with a ceiling value of $10,882.70. This firm fixed-price, non-competitive set-aside delivery order is scheduled for completion by August 5, 2025, and will be fulfilled from the contractor's corporate office location in Conshohocken, Pennsylvania. Ontruzant is a biosimilar therapeutic used in oncology treatment, reflecting the...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $10,014.60 for 420 mg vials of Ontruzant on September 9, 2025, with completion scheduled for September 10, 2025. This firm fixed-price contract, issued with no set-aside designation, was competitively awarded by the Defense Logistics Agency's Medical Supply Chain to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Ontruzant 420 mg vials, a biosimilar medication used in cancer treatment. This competitively awarded, non-set-aside contract carries a ceiling value of $18,701.64 and is structured as a firm fixed-price delivery order with an ultimate completion date of April 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order for 420 mg vials of Ontruzant, a trastuzumab biosimilar used in cancer treatment, valued at $11,497.68. Awarded on September 12, 2025, with an ultimate completion date of September 15, 2025, this firm fixed-price contract represents a competitively awarded, non-set-aside delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX)....
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ontruzant 150 mg vials, a biosimilar to trastuzumab used in cancer treatment. This firm fixed-price delivery order, valued at $6,808.01, represents a non-competitive set-aside contract and carries an ultimate completion date of July 28, 2025. The award is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,071.48 on June 2, 2025, for the supply of Ontruzant 150 mg vials under a firm fixed-price contract with the Defense Department's Medical Supply Chain. This is a non-set-aside award with an ultimate completion date of June 3, 2025, and performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. Ontruzant is a biosimilar monoclonal antibody used in oncology treatments, reflecting the federal...
- The Defense Logistics Agency awarded a $5,748.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ontruzant 420 mg vials, with an ultimate completion date of August 22, 2025. The contract, issued on August 21, 2025, is a non-set-aside award reflecting open competition. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, serving as the prime contractor with no subcontractors identified. This...
- The Defense Logistics Agency awarded a $2,310.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ontruzant 150 mg vials, with an ultimate completion date of September 12, 2025. This non-set-aside delivery order was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order totaling $6,647.56 to AmerisourceBergen Drug Corp for the supply of Ontruzant 420 mg vials. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation, completed on August 4, 2025, with a final delivery date of August 5, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for 150 mg vials of Ontruzant, a biosimilar medication, valued at $7,045.40. This contract was competitively awarded without a set-aside designation on September 8, 2025, with an ultimate completion date of September 9, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...